Re: Cetuximab Therapy and Symptomatic Hypomagnesemia

need to be clarifi ed by further studies. KADRI ALTUNDAG OZDEN ALTUNDAG MAURICIO Z. BAPTISTA SELAHATTIN TUREN MUSTAFA A. ATIK REFERENCES (1) Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypo magnesemia. J Natl Cancer Inst 2005 ; 97 : 1221 4.

Saved in:

Bibliographic Details
Published in:	JNCI : Journal of the National Cancer Institute Vol. 97; no. 23; pp. 1791 - 1792
Main Authors:	Altundag, Kadri, Altundag, Ozden, Baptista, Mauricio Z., Turen, Selahattin, Atik, Mustafa A.
Format:	Journal Article
Language:	English
Published:	United States Oxford University Press 07-12-2005 Oxford Publishing Limited (England)
Subjects:	Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Cetuximab Drug therapy Enzyme Inhibitors - pharmacology Erlotinib Hydrochloride Humans Magnesium Magnesium - blood Magnesium Deficiency - blood Magnesium Deficiency - chemically induced Medical disorders Protein-Tyrosine Kinases - antagonists & inhibitors Quinazolines - pharmacology Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - metabolism
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	need to be clarifi ed by further studies. KADRI ALTUNDAG OZDEN ALTUNDAG MAURICIO Z. BAPTISTA SELAHATTIN TUREN MUSTAFA A. ATIK REFERENCES (1) Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypo magnesemia. J Natl Cancer Inst 2005 ; 97 : 1221 4.
Bibliography:	ark:/67375/HXZ-PL1K3B0P-M local:dji412 istex:3E917D293E0BC3899FC99ADB5DD2FE3E820B843E Correspondence to: Kadri Altundag, MD, 8181 Fannin St., No. 728, Houston, TX 77054 (e-mail: drkadri@usa.net).
ISSN:	0027-8874 1460-2105
DOI:	10.1093/jnci/dji412